AbbVie announced preliminary positive results from phase 3 SELECT-GCA study showing remission in 46% of #GCA pts Rx w/ upadacitinib for 52wks (vs 29% PBO); RCT included a 26-wk steroid taper regimen https://t.co/DIstJ4hazo https://t.co/VXc7rj0REJ
Links:
Phase 3 SELECT-GCA Study of Upadacitinib (RINVOQ®) Showed Positive Results in P…
https://buff.ly/44fwcoY
Apr-22-2024
